Table 3. Relations between Lnc THRIL and MiR-125b and clinical data in UC patients.

		miR-125b				Lnc THRIL
		Median	IQR		P-value	Median	IQR		P-value
Sex	Female	0.27	0.18	0.6	0.208	10.89	10.35	11.4	0.414
	male	0.49	0.23	0.63		11.12	10.21	12.45
Smoker	yes	0.33	0.22	0.57	0.911	10.21	10.18	10.88	0.012*
	no	0.41	0.19	0.61		11.19	10.76	12.45
Coffee consumption	yes	0.34	0.12	0.51	0.417	11.78	11.05	12.53	0.109
	no	0.41	0.21	0.63		10.94	10.18	12.29
Diabetes	yes	0.57	0.31	0.67	0.284	10.18	9.46	11.75	0.159
	no	0.34	0.19	0.6		11.12	10.21	12.45
Hypertension	yes	0.3	0.28	0.31	0.720	11.05	11	11.11	0.902
	no	0.39	0.19	0.62		11.12	10.19	12.45
Hepatobiliary	yes	0.29	0.11	0.36	0.101	12.29	8.25	12.45	0.976
	no	0.45	0.2	0.63		11.06	10.21	12.37
Endocrine	yes	0.73	0.7	0.76	0.041*	10.38	10	10.76	0.239
	no	0.35	0.19	0.61		11.12	10.21	12.45
MC	yes	0.62	0.59	0.64	0.225	11.02	10.7	11.35	0.901
	no	0.35	0.19	0.61		11.11	10.19	12.45
MSK	yes	0.34	0.23	0.55	0.586	10.79	10.18	11.4	0.054
	no	0.43	0.18	0.64		11.12	10.76	12.49
Eye	yes	0.23	0.23	0.41	0.202	11.12	10.89	11.4	0.788
	no	0.43	0.19	0.64		11.06	10.19	12.45
Salicalyates	yes	0.49	0.23	0.64	0.179	10.94	10.18	11.4	0.358
	no	0.32	0.18	0.57		11.19	10.21	12.45
Steroids	yes	0.3	0.18	0.63	0.662	11.11	10.18	12.45	0.482
	no	0.45	0.24	0.59		11.07	10.76	12.37
Azathioprine	yes	0.5	0.23	0.63	0.404	11.01	10.18	11.12	0.194
	no	0.33	0.18	0.61		11.12	10.21	12.45
Infliximab	yes	0.31	0.19	0.64	0.626	11.12	10.18	11.35	0.699
	no	0.39	0.21	0.61		11.06	10.21	12.45